09.07.2024 13:00:07 - dpa-AFX: GNW-Adhoc: Tilray Medical Announces Scientific Study on Medical Cannabis for Patients Over Age 50
BERLIN, July 09, 2024 (GLOBE NEWSWIRE) -- Tilray Medical, a division of Tilray
Brands, Inc. ("Tilray") (Nasdaq: TLRY; TSX: TLRY) and a global leader in medical
cannabis, empowering the therapeutic alliance between patients and healthcare
practitioners to make informed individualized health decisions, today announced
a new Tilray-led scientific publication titled, Medical Cannabis for Patients
Over Age 50: A Multi-Site, Prospective Study of Patterns of Use and Health
Outcomes. The Medical Cannabis in Older Patients Study
(https://publications.sciences.ucf.edu/cannabis/index.php/Cannabis/article/view/
239) ("MCOPS") is a multi-site, prospective, observational study examining the
real-world impact of medical use on patients over the age of 50 and under the
guidance of a healthcare provider.
The MCOPS study comprised of 299 participants with an average age of 66.7 years
and 62.2% of respondents identified as female. Approximately 90% of patients
used medical cannabis to treat pain-related conditions such as chronic pain and
arthritis. This study presents to the medical and scientific community the
impact of medical cannabis on health outcomes, with a focus on pain, sleep and
quality of life.
Under medical cannabis guidance and care, the MCOPs shows correlation with
improvements in pain scores, sleep and quality of life in a still growing subset
of patients. A significant reduction of co-medication was observed, indicating
that the treatment with medical cannabis can be a cost-effective option for this
population.
José Tempero, Tilray's Medical Director, stated, "Our involvement in this
initiative underscores our unwavering commitment to advancing medical research
and highlights our dedication to providing products that supports the findings
to the comprehensive research that bring us one step closer to unlocking the
full therapeutic potential of medical cannabis, especially reinforcing its role
as a treatment option for an aging population."
Tilray Medical's mission is to continue transforming lives and fostering dignity
for patients in need through access to medical cannabis, and today is a leading
provider of EU-GMP certified medical cannabis products in over 20 countries with
a comprehensive portfolio of THC and CBD products. Tilray has supported medical
trials globally, across Europe, Canada, the United States, Australia, and Latin
America, studying the efficacy of medical cannabis as a treatment for
indications including pediatric epilepsy, refractory pediatric epilepsy, cancer-
induced nausea and vomiting, HIV, essential tremor, breast cancer disorders,
post-traumatic stress disorder, and alcohol use disorders.
About Tilray Medical
Tilray Medical is dedicated to transforming lives and fostering dignity for
patients in need through safe and reliable access to a global portfolio of
medical cannabis brands, including Tilray, Aphria, Broken Coast, Symbios and
Navcora. Tilray grew from being one of the first companies to become an approved
licensed producer of medical cannabis in Canada to building the first GMP-
certified cannabis production facilities in Europe, first in Portugal and later
in Germany. Today, Tilray Medical is one of the largest suppliers of medical
cannabis to patients, physicians, hospitals, pharmacies, researchers, and
governments, in 20 countries and across five continents.
For more information on Tilray Medical, visit Tilray Medical Europe
(https://www.globenewswire.com/Tracker?data=m1Az_-
tnZsDoxlCSp1pH3PiHCRFdInquYDLx5KVOa5GvwgptPn-Y03vYkHWZuF7Rh0qzejtpD0bwQw5JnkE1N-
U1p6NjeMmon6R86RJPFAM=), Tilray Medical Canada
(https://www.globenewswire.com/Tracker?data=m1Az_-
tnZsDoxlCSp1pH3M7b_XWARNG39Rhp4xd_74ETPGRj-
em6EdbrJPXjQUkShShdXNmHTuUrEACd5ypVnDKFsbnrvkhk13DIfhM-B8Y=), and Tilray Medical
Australia-New Zealand (https://www.globenewswire.com/Tracker?data=m1Az_-
tnZsDoxlCSp1pH3HeDgfzU3JETDxn_Mpdiawn_9p19CEaojZ8oRT7lcU-RvyLW7rZ-
zlbpHV1Op52byqeZmwj_WQtRZZZ-
kluYPvIbFvWYFney9hFXb7pRaj41qM9VasXi_RLhwyriMjmqgA==).
About Tilray Brands
Tilray Brands, Inc. (Nasdaq: TLRY; TSX: TLRY), is a leading global cannabis-
lifestyle and consumer packaged goods company with operations in Canada, the
United States, Europe, Australia, and Latin America that is changing people's
lives for the better - one person at a time. Tilray Brands delivers on this
mission by inspiring and empowering the worldwide community to live their very
best life and providing access to products that meet the needs of their mind,
body, and soul while invoking wellbeing. Patients and consumers trust Tilray
Brands to deliver a cultivated experience and health and wellbeing through high-
quality, differentiated brands and innovative products. A pioneer in cannabis
research, cultivation, and distribution, Tilray's unprecedented production
platform supports over 20 brands in over 20 countries, including comprehensive
cannabis offerings, hemp-based foods, and craft beverages.
For more information on how we open a world of wellbeing, visit www.Tilray.com
(https://www.globenewswire.com/Tracker?data=fzsvaN9xcjfuytJbRROM8P8EfXdyJ5CovSdR
FsN99rXTVzlcyrmVWdiYCWOgUWWiwbZZoaGnvgnQs_u9-0OhNQ==).
Contacts:
Tilray Brands: news@tilray.com (mailto:news@tilray.com)
Investors: investors@tilray.com (mailto:investors@tilray.com)
Â